Further clinical studies would be essential to establish the efficacy and safety of PI3K/mTOR/AKT targeting in the treatment of MCC, while current data suggest that a synergistic combination of PI3K/mTOR/AKT inhibitors along with other agents might offer an antitumor effect [218]. This evidence concerns the gene AKT1 and Merkel cell skin cancer.